Topical hormone estriol

PreclinicalSmall molecule

MMeLSyTech, Ltd

Topical hormone estriol is one of 33 small molecule programs targeting Atrophy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtrophyActive, not recruiting

AtrophyPreclinical

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Atrophy

#DrugCompanyPhaseTrials

Activella

Eli Lilly

Phase 3

1 2

Actos

Takeda

Phase 3

1 3

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 4

Pitocin

RRetrophin

Phase 3

4 5

Avandia

Alnylam Pharmaceuticals

Phase 2

1 6

Protease Inhibitors

Tibotec Pharmaceuticals, Ireland

Approved

1 7

Protease Inhibitor

MMedical Research Council

Approved

1 8

Genotropin

EMD Serono

Phase 2

1 9

Avodart

Akero Therapeutics

Phase 2

1 10

Prometrium

Ferring

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy2 trials

Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser

Recruiting·MMeLSyTech, Ltd·N/A·NCT05335317·120 enrolled

Vulvovaginal Atrophy Correction Using Neodymium Laser

Completed·MMeLSyTech, Ltd·N/A·NCT04735549·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Topical hormone estriol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical hormone estriol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical hormone estriol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MeLSyTech, Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMeLSyTech, Ltd

Topical hormone estriol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophy2 trials

References

Drug Info

Quick Facts

Related News